Oncopeptides AB Statistics
Oncopeptides AB (OND) Stock Statistics & Valuation Metrics
Total Valuation
Oncopeptides AB has a market cap or net worth of EUR 69.90M. The enterprise value is EUR 857.23M.
- Market Cap
- EUR 69.90M
- Enterprise Value
- EUR 857.23M
Share Statistics
Oncopeptides AB has 431,357,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 431,357,760
- Owned by Insiders
- 0.68%
- Owned by Institutions
- ―
Financial Efficiency
Oncopeptides AB’s return on equity (ROE) is 4.24 and return on invested capital (ROIC) is -230.36%.
- Return on Equity (ROE)
- 4.24
- Return on Assets (ROA)
- -1.85
- Return on Invested Capital (ROIC)
- -230.36%
- Return on Capital Employed (ROCE)
- -2.50
- Revenue Per Employee
- 948.24K
- Profits Per Employee
- -3.33M
- Employee Count
- 75
- Asset Turnover
- 0.53
- Inventory Turnover
- 1.47
Valuation Ratios
The current PE Ratio of Oncopeptides AB is -2.79. Oncopeptides AB’s PEG ratio is -0.04.
- PE Ratio
- -2.79
- PS Ratio
- 7.34
- PB Ratio
- -39.10
- Price to FCF
- -3.94
- Price to Operating Cash Flow
- -3.35
- PEG Ratio
- -0.04
Income Statement
In the last 12 months, Oncopeptides AB had revenue of 71.12M and earned -249.59M in profits. Earnings per share was -1.10.
- Revenue
- 71.12M
- Gross Profit
- 59.00M
- Operating Income
- -225.89M
- Pretax Income
- -248.17M
- Net Income
- -249.59M
- EBITDA
- -219.26M
- Earnings Per Share (EPS)
- -1.10
Cash Flow
In the last 12 months, operating cash flow was -188.56M and capital expenditures 0, giving a free cash flow of -188.56M billion.
- Operating Cash Flow
- -188.56M
- Free Cash Flow
- -188.56M
- Free Cash Flow per Share
- -0.53
Dividends & Yields
Oncopeptides AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -25.37%
- Earnings Yield
- -30.40%
Stock Price Statistics
- Beta
- 0.37
- 52-Week Price Change
- -58.48%
- 50-Day Moving Average
- 0.17
- 200-Day Moving Average
- 0.16
- Relative Strength Index (RSI)
- 51.88
- Average Volume (3m)
- 5,228
Important Dates
Oncopeptides AB upcoming earnings date is Feb 18, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Oncopeptides AB as a current ratio of 2.63, with Debt / Equity ratio of -236.69%
- Current Ratio
- 2.63
- Quick Ratio
- 2.45
- Debt to Market Cap
- 0.12
- Net Debt to EBITDA
- -0.26
- Interest Coverage Ratio
- -15.63
Taxes
In the past 12 months, Oncopeptides AB has paid 1.42M in taxes.
- Income Tax
- 1.42M
- Effective Tax Rate
- -0.01
Enterprise Valuation
Oncopeptides AB EV to EBITDA ratio is -4.34, with an EV/FCF ratio of -4.06.
- EV to Sales
- 7.56
- EV to EBITDA
- -4.34
- EV to Free Cash Flow
- -4.06
- EV to Operating Cash Flow
- -4.06
Balance Sheet
Oncopeptides AB has EUR 157.61M in cash and marketable securities with EUR 135.17M in debt, giving a net cash position of EUR 22.44M billion.
- Cash & Marketable Securities
- EUR 157.61M
- Total Debt
- EUR 135.17M
- Net Cash
- EUR 22.44M
- Net Cash Per Share
- EUR 0.05
- Tangible Book Value Per Share
- EUR 0.07
Margins
Gross margin is 96.52%, with operating margin of -184.06%, and net profit margin of -189.41%.
- Gross Margin
- 96.52%
- Operating Margin
- -184.06%
- Pretax Margin
- -187.63%
- Net Profit Margin
- -189.41%
- EBITDA Margin
- -174.17%
- EBIT Margin
- -184.06%
Analyst Forecast
The average price target for Oncopeptides AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 69.05%
- EPS Growth Forecast
- 41.69%
